Oleanolic Acid and Alzheimer’s Disease: Mechanistic Hypothesis of Therapeutic Potential
Source abstract
Abstract
Numerous hypotheses have been proposed to explain the origin of Alzheimer’s disease (AD), a chronic neurodegenerative disorder that currently has no curative treatment. These hypotheses include the abnormal accumulation of β-amyloid and hyperphosphorylated Tau, degeneration of cholinergic neurons associated with chronic neuroinflammation and oxidative stress, and dysregulation of lipid and carbohydrate metabolism. oleanolic acid (OA), a pentacyclic triterpenoid widely distributed across plant species, has demonstrated anti-inflammatory and antioxidant activities, anti-aggregation properties, together with regulatory effects on carbohydrate and lipid metabolism. Given the diversity of hypotheses proposed for AD and its multifactorial nature, the pleiotropic actions of OA positions it as a promising candidate for preventive and therapeutic strategies. This review compiles evidence on OA and selected synthetic derivatives, analyzing their impact across the major mechanistic hypotheses of AD pathogenesis. Collectively, these findings support OA as a promising candidate to address protein aggregation, metabolic imbalance, and neuroinflammation in AD.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Natural product bioactivities and synthesis · Genomics, phytochemicals, and oxidative stress · Pharmacological Effects of Natural Compounds
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Food and Health, Instituto de la Grasa-CSIC, Campus of the University Pablo de Olavide, 41013 Seville, Spain
Department of Nursing, Faculty of Health Sciences, University of Granada, 18016 Granada, Spain
Instituto de Investigación Biosanitaria (ibs.GRANADA), 18014 Granada, Spain
References (100+)
Show source-provided references
1. the Complexity of Alzheimer’S Disease: An Evolving Puzzle10.1152/physrev.00015.2020 ↗
2. Alzheimer’s Association (2025). 2025 Alzheimer’s disease facts and figures. Alzheimer’s Dement., 11, 332–384.
3. The Alzheimer’s Disease Exposome10.1016/j.jalz.2019.06.3914 ↗
4. Critical assessment of anti-amyloid-β monoclonal antibodies effects in Alzheimer’s disease: A systematic review and meta-analysis highlighting target engagement and clinical meaningfulness10.1038/s41598-024-75204-8 ↗
5. Van Bulck, M., Sierra-Magro, A., Alarcon-Gil, J., Perez-Castillo, A., and Morales-Garcia, J.A. (2019). Novel approaches for the treatment of alzheimer’s and parkinson’s disease. Int. J. Mol. Sci., 20.10.3390/ijms20030719 ↗
6. Castellano, J.M., Ramos-Romero, S., and Perona, J.S. (2022). Oleanolic Acid: Extraction, Characterization and Biological Activity. Nutrients, 14.10.3390/nu14030623 ↗
7. Fernández-Aparicio, Á., Correa-Rodríguez, M., Castellano, J.M., Schmidt-RioValle, J., Perona, J.S., and González-Jiménez, E. (2022). Potential Molecular Targets of Oleanolic Acid in Insulin Resistance and Underlying Oxidative Stress: A Systematic Review. Antioxidants, 11.10.3390/antiox11081517 ↗
8. The amyloid hypothesis of Alzheimer’s disease at 25 years10.15252/emmm.201606210 ↗
9. Tolar, M., Hey, J., Power, A., and Abushakra, S. (2021). Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression. Int. J. Mol. Sci., 22.10.3390/ijms22126355 ↗
10. β-Amyloid precursor protein (βAPP) in human gut with special reference to the enteric nervous system10.1016/0361-9230(95)02006-D ↗
11. APP Protein Family Signaling at the Synapse: Insights from Intracellular APP-Binding Proteins
12. Iannuzzi, C., Irace, G., and Sirangelo, I. (2014). Differential effects of glycation on protein aggregation and amyloid formation. Front. Mol. Biosci., 1.10.3389/fmolb.2014.00009 ↗
13. APP Processing and Synaptic Function10.1016/S0896-6273(03)00124-7 ↗
14. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function10.1038/nn1372 ↗
15. Naturally secreted oligomers of amyloid b protein potently inhibit hippocampal long-term potentiation in vivo10.1038/416535a ↗
16. AMPA-R Removal Underlies Aβ-induced Synaptic Depression and Dendritic Spine Loss10.1016/j.neuron.2006.10.035 ↗
17. Amyloid-β protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory10.1038/nm1782 ↗
18. Identification of neurotoxic cross-linked amyloid-β dimers in the Alzheimer’s brain10.1093/brain/awz066 ↗
19. A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer’s brain10.1111/jnc.15007 ↗
20. The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics10.1126/science.1072994 ↗
21. Imaging vascular disease and amyloid in the aging brain: Implications for treatment
22. Gagno, G., Ferro, F., Fluca, A.L., Janjusevic, M., Rossi, M., Sinagra, G., Beltrami, A.P., Moretti, R., and Aleksova, A. (2020). From brain to heart: Possible role of amyloid-β in ischemic heart disease and ischemia-reperfusion injury. Int. J. Molec. Sci., 21.10.3390/ijms21249655 ↗
23. Therapeutic Potential of Nitrogen-Substituted Oleanolic Acid Derivatives in Neuroinflammatory and Cytokine Pathways: Insights From Cell-Based and Computational Models10.1002/cbdv.202500269 ↗
24. Aralia cordata Protects Against Amyloid β Protein (25–35)–Induced Neurotoxicity in Cultured Neurons and Has Antidementia Activities in Mice10.1254/jphs.08271FP ↗
25. Inhibition of amyloid β aggregation and protective effect on SH-SY5Y cells by triterpenoid saponins from the cactus Polaskia chichipe10.1016/j.bmc.2017.04.023 ↗
26. Triterpene saponins from the roots of Dipsacus asper and their protective effects against the Aβ25–35 induced cytotoxicity in PC12 cells10.1016/j.fitote.2012.03.004 ↗
27. Amyloid β aggregation inhibitory activity of triterpene saponins from the cactus Stenocereus pruinosus10.1007/s11418-020-01463-0 ↗
28. Oleanane triterpenoids from Akebiae Caulis exhibit inhibitory effects on Aβ42 induced fibrillogenesis10.1007/s12272-016-0885-7 ↗
29. Evaluation of the Antioxidant and Anti-Alzheimer’s Activity of Oleanolic Acid: An In-vitro Study
30. Dual activities of the anti-cancer drug candidate PBI-05204 provide neuroprotection in brain slice models for neurodegenerative diseases and stroke10.1038/srep25626 ↗
31. Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer’s disease10.1111/j.1471-4159.2009.05970.x ↗
32. Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 69510.1074/jbc.M100710200 ↗
33. The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection10.1186/1742-2094-5-14 ↗
34. Oleanolic Acid Ameliorates Aβ25-35 Injection-induced Memory Deficit in Alzheimer’s Disease Model Rats by Maintaining Synaptic Plasticity10.2174/1871527317666180525113109 ↗
35. Continuous Infusion of BETA-Amyloid Protein into the Rat Cerebral Ventricle Induces Learning Impairment and Neuronal and Morphological Degeneration10.1254/jjp.60.51 ↗
36. Reversal of neuronal tau pathology via adiponectin receptor activation10.1038/s42003-024-07391-z ↗
37. Tau in Alzheimer Disease and Related Tauopathies10.2174/156720510793611592 ↗
38. Molecular Mechanisms of ER Stress and UPR in the Pathogenesis of Alzheimer’s Disease10.1007/s12035-020-01929-y ↗
39. Synergy between amyloid-β and tau in Alzheimer’s disease10.1038/s41593-020-0687-6 ↗
40. Effects of Heparan Sulfate Trisaccharide Containing Oleanolic Acid in Attenuating Hyperphosphorylated Tau-Induced Cell Dysfunction Associated with Alzheimer’s Disease10.1021/acs.jmedchem.4c02563 ↗
41. Anti-inflammatory Potential of GSK-3 Inhibitors10.2174/1389450122666210118150313 ↗
42. 20(S)-protopanaxadiol and oleanolic acid ameliorate cognitive deficits in APP/PS1 transgenic mice by enhancing hippocampal neurogenesis10.1016/j.jgr.2020.07.003 ↗
43. Proteins with cognition-associated structural changes in a rat model of aging exhibit reduced refolding capacity10.1126/sciadv.adt3778 ↗
44. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease10.1093/brain/awy132 ↗
45. Acetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior10.1016/j.neuron.2012.08.036 ↗
46. Fahnestock, M., and Shekari, A. (2019). ProNGF and Neurodegeneration in Alzheimer’s Disease. Front. Neurosci., 13.10.3389/fnins.2019.00129 ↗
47. Cholinergic modulation of the hippocampal region and memory function10.1111/jnc.14052 ↗
48. Sam, C., and Bordoni, B. (2025). Physiology, Acetylcholine, StatPearls.
49. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine10.1016/S0306-4522(01)00613-3 ↗
50. Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer’s Disease10.1001/jama.1994.03510370044030 ↗
51. Hussain, A., and Bloemer, J. (2023). Side effects of drugs used in the treatment of Alzheimer’s disease. Side Effects of Drugs Annual, Elsevier.
52. A Current Perspective on the Inhibition of Cholinesterase by Natural and Synthetic Inhibitors10.2174/1389200218666161123122734 ↗
53. Bhadra, S., Dalai, M.K., Chanda, J., and Mukherjee, P.K. (2015). Evaluation of Bioactive Compounds as Acetylcholinesterase Inhibitors from Medicinal Plants. Evidence-Based Validation of Herbal Medicine, Elsevier.10.1016/B978-0-12-800874-4.00013-1 ↗
54. A Novel Isopimarane Diterpenoid with Acetylcholinesterase Inhibitory Activity from Nepeta sorgerae, an Endemic Species to the Nemrut Mountain
55. Elsholtzia rugulosa: Phytochemical Profile and Antioxidant, Anti-Alzheimer’s Disease, Antidiabetic, Antibacterial, Cytotoxic and Hepatoprotective Activities10.1007/s11130-021-00941-4 ↗
56. Phytochemical Analysis and Evaluation of Biological Activity of Lawsonia inermis Seeds Related to Alzheimer’s Disease
57. Ali, M., Muhammad, S., Shah, M.R., Khan, A., Rashid, U., Farooq, U., Ullah, F., Sadiq, A., Ayaz, M., and Ali, M. (2017). Neurologically Potent Molecules from Crataegus oxyacantha; Isolation, Anticholinesterase Inhibition, and Molecular Docking. Front. Pharmacol., 8.10.3389/fphar.2017.00327 ↗
58. Effect-directed analysis of fresh and dried elderberry (Sambucus nigra L.) via hyphenated planar chromatography10.1016/j.chroma.2015.11.021 ↗
59. Terpenoids of the micromerias.-I. Two new triterpenic acids isolatedfrom micromeria benthami webb et berth10.1016/S0040-4039(01)89574-5 ↗
60. An updated review on the parasitic herb of Cuscuta reflexa Roxb10.3736/jcim20120302 ↗
61. Bioactive constituents of Salvia chrysophylla Stapf10.1080/14786419.2012.734820 ↗
62. Chemometric guided isolation of new triterpenoid saponins as acetylcholinesterase inhibitors from seeds of Achyranthes bidentata Blume10.1016/j.fitote.2024.105925 ↗
63. Ursolic and oleanolic acid derivatives with cholinesterase inhibiting potential10.1016/j.bioorg.2018.12.013 ↗
64. Terpenes and Phenylpropanoids as Acetyl- and Butyrylcholinesterase Inhibitors: A Comparative Study10.2174/1567205016666191010105115 ↗
65. Anti-inflammatory, antioxidant and anti-acetylcholinesterase activities of Bouvardia ternifolia: Potential implications in Alzheimer’s disease10.1007/s12272-015-0587-6 ↗
66. In silico molecular docking and dynamic simulation of anti-cholinesterase compounds from the extract of Catunaregam spinosa for possible treatment of Alzheimer’s disease10.1016/j.heliyon.2024.e27880 ↗
67. Stępnik, K., Kukula-Koch, W., Plazinski, W., Rybicka, M., and Gawel, K. (2023). Neuroprotective Properties of Oleanolic Acid—Computational-Driven Molecular Research Combined with In Vitro and In Vivo Experiments. Pharmaceuticals, 16.10.20944/preprints202308.1503.v1 ↗
68. N-methylated diazabicyclo [3.2.2]nonane substituted triterpenoic acids are excellent, hyperbolic and selective inhibitors for butyrylcholinesterase10.1016/j.ejmech.2021.113947 ↗
69. Diethoxyphosphoryloxy-oleanolic acid is a nanomolar-inhibitor of butyrylcholinesterase10.1111/cbdd.14506 ↗
70. Loesche, A., Kahnt, M., Serbian, I., Brandt, W., and Csuk, R. (2019). Triterpene-Based Carboxamides Act as Good Inhibitors of Butyrylcholinesterase. Molecules, 24.10.3390/molecules24050948 ↗
71. Synthesis of nitrogen-containing oleanolic acid derivatives as carbonic anhydrase and acetylcholinesterase inhibitors10.1007/s00044-023-03031-z ↗
72. Petrova, A.V., Zueva, I.V., and Petrov, K.A. (2023). Synthesis and Cholinesterase Inhibitory Potency of 2,3-Indolo-oleanolic Acid and Some Related Derivatives. Molbank, 2023.10.3390/M1739 ↗
73. The presence of a cationic center is not alone decisive for the cytotoxicity of triterpene carboxylic acid amides10.1016/j.steroids.2020.108713 ↗
74. Hoenke, S., Christoph, M.A., Friedrich, S., Heise, N., Brandes, B., Deigner, H.P., Al-Harrasi, A., and Csuk, R. (2021). The Presence of a Cyclohexyldiamine Moiety Confers Cytotoxicity to Pentacyclic Triterpenoids. Molecules, 26.10.3390/molecules26072102 ↗
75. Oleanolic acid ameliorates cognitive dysfunction caused by cholinergic blockade via TrkB-dependent BDNF signaling10.1016/j.neuropharm.2016.07.029 ↗
76. Effects of scopolamine on extracellular acetylcholine and choline levels and on spontaneous motor activity in freely moving rats measured by brain dialysis10.1016/0091-3057(89)90438-3 ↗
77. BDNF-induced local protein synthesis and synaptic plasticity10.1016/j.neuropharm.2013.04.005 ↗
78. BDNF-TrkB signaling through Erk1/2MAPK phosphorylation mediates the enhancement of fear memory induced by glucocorticoids10.1038/mp.2013.134 ↗
79. Ursolic acid and its isomer oleanolic acid are responsible for the anti-dementia effects of Ocimum sanctum in olfactory bulbectomized mice10.1007/s11418-022-01609-2 ↗
80. Thompson, M.B., Tirupattur, S.P., Vishwakarma, N., and Katwa, L.C. (2025). Essential Pieces of the Puzzle: The Roles of VEGF and Dopamine in Aging. Cells, 14.10.3390/cells14151178 ↗
81. Possible involvement of VEGF signaling system in rescuing effect of endogenous acetylcholine on NMDA-induced long-lasting hippocampal cell damage in organotypic hippocampal slice cultures10.1016/j.neuint.2014.05.009 ↗
82. Endogenous acetylcholine regulates neuronal and astrocytic vascular endothelial growth factor expression levels via different acetylcholine receptor mechanisms10.1016/j.neuint.2018.04.012 ↗
83. Release of acetylcholine to raise insulin secretion in Wistar rats by oleanolic acid, one of the active principles contained in Cornus officinalis10.1016/j.neulet.2006.05.025 ↗
84. Neuroinflammation in Alzheimer disease10.1038/s41577-024-01104-7 ↗
85. Solito, E., and Sastre, M. (2012). Microglia function in Alzheimer’s disease. Front. Pharmacol., 3.10.3389/fphar.2012.00014 ↗
86. Sierra, A., Tremblay, M.Ã., and Wake, H. (2014). Never-resting microglia: Physiological roles in the healthy brain and pathological implications. Front. Cell Neurosci., 8.10.3389/fncel.2014.00240 ↗
87. Neuroinflammation in Alzheimer’s disease10.1016/S1474-4422(15)70016-5 ↗
88. A meta-analysis of cytokines in Alzheimer’s disease10.1016/j.biopsych.2010.06.012 ↗
89. Microglia and amyloid plaque formation in Alzheimer’s disease—Evidence, possible mechanisms, and future challenges10.1016/j.jneuroim.2024.578342 ↗
90. Dark microglia: A new phenotype predominantly associated with pathological states10.1002/glia.22966 ↗
91. Microglial priming in neurodegenerative disease10.1038/nrneurol.2014.38 ↗
92. Oleanolic Acid and Related Triterpenoids from Olives on Vascular Function: Molecular Mechanisms and Therapeutic Perspectives10.2174/0929867322666141212122921 ↗
93. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity
94. Natural triterpenes modulate immune-inflammatory markers of experimental autoimmune encephalomyelitis: Therapeutic implications for multiple sclerosis10.1111/j.1476-5381.2012.01869.x ↗
95. Castellano, J.M., Garcia-Rodriguez, S., Espinosa, J.M., Millan-Linares, M.C., Rada, M., and Perona, J.S. (2019). Oleanolic acid exerts a neuroprotective effect against microglial cell activation by modulating cytokine release and antioxidant defense systems. Biomolecules, 9.10.3390/biom9110683 ↗
96. Oleanolic acid administration alleviates neuropathic pain after a peripheral nerve injury by regulating microglia polarization-mediated neuroinflammation10.1039/C9RA10388K ↗
97. Oleanolic acid protects against cognitive decline and neuroinflammation-mediated neurotoxicity by blocking secretory phospholipase A2 IIA-activated calcium signals10.1016/j.molimm.2018.04.015 ↗
98. Malva parviflora extract ameliorates the deleterious effects of a high fat diet on the cognitive deficit in a mouse model of Alzheimer’s disease by restoring microglial function via a PPAR-γ-dependent mechanism10.1186/s12974-019-1515-3 ↗
99. NF-κB signaling in inflammation10.1038/sigtrans.2017.23 ↗
100. Oleanolic acid-based therapeutics ameliorate rotenone-induced motor and depressive behaviors in parkinsonian male mice via controlling neuroinflammation and activating Nrf2-BDNF-dopaminergic signaling pathways10.1080/15376516.2023.2288198 ↗